S Salmeron, L Brochard, H Mal, A Tenaillon, M Henry-Amar, D Renon, P Duroux and G Simonneau
Service de Pneumologie et Reanimation, Hopital Antoine Beclere, Clamart, France.

In a multicenter, randomized, double-blind study, we compared the effects of nebulized (5 mg x 2) and intravenous (0.5 mg) albuterol (salbutamol) over 1 h in 47 patients admitted to hospital with severe acute asthma defined as a peak expiratory flow (PEF) below 150 L/min and hypercapnia (Pa(CO2) > or = 40 mm Hg). Additional treatment included nasal oxygen and hydrocortisone succinate. The efficacy was assessed after 1 h. In the group treated by nebulization (NEB group, n = 22) 19 (86%) patients (95% confidence interval: 65 to 97%) had been treated successfully according to predefined criteria, versus 12 (48%) patients (95% confidence interval: 28 to 69%) in the intravenously treated group (i.v. group, n = 25), p = 0.006. The mean increase in PEF was greater in the NEB group than in the i.v. group (+107 +/- 94 L/min versus +42 +/- 66 L/min, p = 0.01) as well as the decrease in Pa(CO2) values (-10 +/- 5 mm Hg versus -2 +/- 12 mm Hg, p < 0.01). Beta agonist- induced hypokalemia was more pronounced in the i.v. group than in the NEB group. We conclude that, in hypercapnic acute asthma, the nebulized route has a greater efficacy and fewer side effects than the intravenous route.

This article has been cited by other articles:

				S. Aldington and R. Beasley Asthma exacerbations {middle dot} 5: Assessment and management of severe asthma in adults in hospital Thorax, May 1, 2007; 62(5): 447 - 458. [Abstract] [Full Text] [PDF]

				E. R. McFadden Jr. Acute Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759. [Abstract] [Full Text] [PDF]

				P Phipps and C S Garrard The pulmonary physician in critical care * 12: Acute severe asthma in the intensive care unit Thorax, January 1, 2003; 58(1): 81 - 88. [Abstract] [Full Text] [PDF]

				C. Faisy, E. Naline, J.-L. Diehl, X. Emonds-Alt, T. Chinet, and C. Advenier In vitro sensitization of human bronchus by beta 2-adrenergic agonists Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1033 - L1042. [Abstract] [Full Text] [PDF]

				J. Varon, R. E. Fromm Jr, and P. E. Marik IV 2{beta} or Not 2{beta}, That Is the Question! Chest, October 1, 2002; 122(4): 1116 - 1118. [Full Text] [PDF]

				A. H. Travers, B. H. Rowe, S. Barker, A. Jones, and C. A. Camargo Jr The Effectiveness of IV {beta}-Agonists in Treating Patients With Acute Asthma in the Emergency Department: A Meta-analysis Chest, October 1, 2002; 122(4): 1200 - 1207. [Abstract] [Full Text] [PDF]

				M. FitzGerald Extracts from ""Clinical Evidence"": Acute asthma BMJ, October 13, 2001; 323(7317): 841 - 845. [Full Text] [PDF]

				H. W. Kelly The Management of Acute Severe Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 91 - 107. [Abstract] [PDF]

				M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]

				Management of patients with asthma in the emergency department and in hospital Can. Med. Assoc. J., November 1, 1999; 161(90111): s53 - 59. [Full Text]

				J. A. Everett Alternatives to Standard Status Asthmaticus Therapy Journal of Pharmacy Practice, June 1, 1997; 10(3): 186 - 199. [Abstract] [PDF]

				Using {beta}2-stimulants in asthma DTB, January 1, 1997; 35(1): 1 - 4. [Abstract] [Full Text] [PDF]

				North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults BMJ, March 23, 1996; 312(7033): 762 - 766. [Full Text]